B A Teicher

Summary

Affiliation: Genzyme Corporation
Country: USA

Publications

  1. doi Antiangiogenic agents and targets: A perspective
    Beverly A Teicher
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Biochem Pharmacol 81:6-12. 2011
  2. ncbi Protein kinase C as a therapeutic target
    Beverly A Teicher
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Clin Cancer Res 12:5336-45. 2006
  3. ncbi Transforming growth factor-beta and the immune response to malignant disease
    Beverly A Teicher
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Clin Cancer Res 13:6247-51. 2007
  4. doi Newer cytotoxic agents: attacking cancer broadly
    Beverly A Teicher
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Clin Cancer Res 14:1610-7. 2008
  5. ncbi Tumor models for preclinical development of targeted agents
    Beverly A Teicher
    Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701, USA
    Prog Drug Res 63:43-66. 2005
  6. doi Acute and chronic in vivo therapeutic resistance
    Beverly A Teicher
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Biochem Pharmacol 77:1665-73. 2009
  7. ncbi Newer vascular targets: endosialin (review)
    Beverly A Teicher
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Int J Oncol 30:305-12. 2007
  8. doi In vivo/ex vivo and in situ assays used in cancer research: a brief review
    Beverly A Teicher
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Toxicol Pathol 37:114-22. 2009
  9. ncbi Antibody-drug conjugate targets
    B A Teicher
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Curr Cancer Drug Targets 9:982-1004. 2009
  10. doi Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs
    Beverly A Teicher
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Curr Opin Pharmacol 10:397-404. 2010

Collaborators

Detail Information

Publications48

  1. doi Antiangiogenic agents and targets: A perspective
    Beverly A Teicher
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Biochem Pharmacol 81:6-12. 2011
    ....
  2. ncbi Protein kinase C as a therapeutic target
    Beverly A Teicher
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Clin Cancer Res 12:5336-45. 2006
  3. ncbi Transforming growth factor-beta and the immune response to malignant disease
    Beverly A Teicher
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Clin Cancer Res 13:6247-51. 2007
    ..Phase I clinical trials of an inhibitor of TGF-beta receptor type I kinase activity and a TGF-beta neutralizing antibody are under way...
  4. doi Newer cytotoxic agents: attacking cancer broadly
    Beverly A Teicher
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Clin Cancer Res 14:1610-7. 2008
    ..The five articles in this issue of CCR Focus present the current status of these next generation cytotoxic agents...
  5. ncbi Tumor models for preclinical development of targeted agents
    Beverly A Teicher
    Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701, USA
    Prog Drug Res 63:43-66. 2005
  6. doi Acute and chronic in vivo therapeutic resistance
    Beverly A Teicher
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Biochem Pharmacol 77:1665-73. 2009
    ..Although some drug resistance developed in vivo is not genetically based or indefinitely stable, this form of therapeutic resistance may be critically important in the clinic...
  7. ncbi Newer vascular targets: endosialin (review)
    Beverly A Teicher
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Int J Oncol 30:305-12. 2007
    ..The selective expression of endosialin by tumor vasculature and stroma has been confirmed. Although the function of endosialin remains to be elucidated, the expression pattern for this protein may be favorable for cancer therapy...
  8. doi In vivo/ex vivo and in situ assays used in cancer research: a brief review
    Beverly A Teicher
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Toxicol Pathol 37:114-22. 2009
    ..Both TNP-470 and enzastaurin have undergone clinical trials. Enzastaurin is currently in Phase III clinical trials...
  9. ncbi Antibody-drug conjugate targets
    B A Teicher
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Curr Cancer Drug Targets 9:982-1004. 2009
    ..While only one antibody-drug conjugate has reached regulatory approval, there are nearly 20 of these in clinical trial. The time may have come for this technology to become a major contributor to improving treatment for cancer patients...
  10. doi Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs
    Beverly A Teicher
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Curr Opin Pharmacol 10:397-404. 2010
    ..Thus, there is still a distance to go in making optimal use of preclinical models to aid in the selection of combination regimens worthy of clinical trial...
  11. doi CXCL12 (SDF-1)/CXCR4 pathway in cancer
    Beverly A Teicher
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Clin Cancer Res 16:2927-31. 2010
    ..The CXCL12/CXCR4 axis is involved in tumor progression, angiogenesis, metastasis, and survival. This pathway is a target for therapeutics that can block the CXCL12/CXCR4 interaction or inhibit downstream intracellular signaling...
  12. ncbi Tumor models for efficacy determination
    Beverly A Teicher
    Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701, USA
    Mol Cancer Ther 5:2435-43. 2006
    ..Each of these types of models has advantages and disadvantages to the "drug hunter" searching for improved treatments...
  13. ncbi Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model
    Jennifer Walter-Yohrling
    Department of Tumor Biology, Genzyme Molecular Oncology, Genzyme Corporation, Five Mountain Road, Framingham, MA 01701, USA
    Cancer Chemother Pharmacol 52:263-9. 2003
    ..In an effort to study the importance of stromal involvement in angiogenesis, we developed a novel, multicellular model that utilizes three of the primary cell types involved in tumor angiogenesis...
  14. ncbi Identification of genes expressed in malignant cells that promote invasion
    Jennifer Walter-Yohrling
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Cancer Res 63:8939-47. 2003
    ..This combination approach appears to be a powerful tool for identifying genes that may be useful as diagnostic markers and/or as therapeutic targets for invasive solid tumors...
  15. doi Netrin-4 regulates angiogenic responses and tumor cell growth
    Mariana Nacht
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Exp Cell Res 315:784-94. 2009
    ..Specifically, Phospho-Akt-1, Phospho-Jnk-2, and Phospho-c-Jun are reduced in tumor cells that have been treated with netrin-4. Together, these data suggest a potential role for netrin-4 in regulating tumor growth...
  16. ncbi Assays for in vitro and in vivo synergy
    Beverly A Teicher
    Genzyme Corporation, Framingham, MA, USA
    Methods Mol Med 85:297-321. 2003
  17. doi Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue Framingham, MA 01701 9322, USA
    Microvasc Res 76:180-8. 2008
    ..Anti-endosialin antibodies may have value in identifying vasculature in malignant tissues. With the appropriate agent, targeting endosialin may interfere with blood vessel growth during tumor development...
  18. doi Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors
    Leslie S Kurtzberg
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Mol Cancer Ther 7:3212-22. 2008
    ..This may be due to greater sensitivity of human bone marrow than mouse to the cytotoxicity of these agents. It may be possible to achieve similar levels of ARC-111 in patients as in mice allowing improved antitumor activity...
  19. doi Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Mol Cancer Ther 7:2536-46. 2008
    ..The data presented here on endothelial genes that are up-regulated in tumor vasculature and in EPC support the hypothesis that the angiogenesis process in cancer can involve EPC...
  20. ncbi The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution
    Cecile Rouleau
    Genzyme Corporation, Framingham, MA 01701, USA
    Int J Oncol 32:739-48. 2008
    ..The therapeutic potential of LeTx needs to be further investigated in non-melanoma tumor models expressing the ANTXR1/TEM8 and/or ANTXR2/CMG2 protein...
  21. ncbi Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function
    Cecile Rouleau
    Genzyme Corp, 1 Mountain Road, Framingham, MA 01701, USA
    Mol Cancer Ther 5:219-29. 2006
    ..These results indicate that PRL-3 is functional in both endothelial cells and malignant cells and further validate PRL-3 as a potentially important molecular target for anticancer therapy...
  22. doi Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence
    Ann Byrne
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Exp Cell Res 316:258-71. 2010
    ..These data support the view that the 19S and 20S subunits of the proteasome have distinct biological functions and imply that targeting 19S and 20S would have distinct molecular consequences on tumor cells...
  23. ncbi Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Int J Oncol 34:619-27. 2009
    ..Endosialin expression by both CAF and MSC further implies the potential contribution of MSC to tumor stroma via differentiation into tumor stromal fibroblasts...
  24. ncbi Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701, USA
    Int J Oncol 34:1329-40. 2009
    ..Bringing together bone marrow toxicity data, tumor cell line cytotoxicity data, and human tumor xenograft efficacy provides valuable information for the translation of preclinical findings to the clinic...
  25. doi sFLT01: a novel fusion protein with antiangiogenic activity
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701, USA
    Mol Cancer Ther 10:404-15. 2011
    ..It is a dual targeting agent that neutralizes both VEGF and PlGF and, therefore, has potential as a next generation antiangiogenic therapeutic for oncology...
  26. ncbi Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model
    Sharon D Morgenbesser
    Department of Oncology Research, Genzyme Corporation, Framingham, MA 01701 9322, USA
    Prostate 67:83-106. 2007
    ..A major focus of prostate cancer research has been to identify genes that are deregulated during tumor progression, potentially providing diagnostic markers and therapeutic targets...
  27. ncbi Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells
    Rebecca G Bagley
    Genzyme Corp, Framingham, Massachusetts 01701 9322, USA
    Cancer Res 63:5866-73. 2003
    ..EPC may be a better model of human tumor endothelial cells than HUVEC and HMVEC and, thus, may provide an improved cell-based model for second generation antineoplastic antiangiogenic drug discovery...
  28. ncbi Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Microvasc Res 71:163-74. 2006
    ..Pericytes displayed invasive action against NSCLC clusters in the absence of other cell types. Perivascular cells contribute to the progression of disease and are an attractive target for anti-angiogenic therapy...
  29. pmc Vascular gene expression in nonneoplastic and malignant brain
    Stephen L Madden
    Genetics and Genomics, 5 Mountain Rd, Framingham, MA 01701, USA
    Am J Pathol 165:601-8. 2004
    ..Additional characterization of this extensive brain endothelial cell gene expression database will provide unique molecular insights into vascular gene expression...
  30. ncbi Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy
    Rebecca G Bagley
    Genzyme Corp, Framingham, Massachusetts 01701 9322, USA
    Cancer Res 65:9741-50. 2005
    ..These results support the notion that pericytes and EPC contribute to malignancy and that these cell types can be useful as cell-based models for tumor vascular development and selection of agents that may provide therapeutic benefit...
  31. doi Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents
    Leslie S Kurtzberg
    Genzyme Corporation, Framingham, MA 01701, USA
    Cancer Chemother Pharmacol 64:1029-38. 2009
    ..The bone marrow toxicity and human tumor xenograft activity of three tubulin-binding compounds, vincristine, paclitaxel, and tasidotin were compared...
  32. doi Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma
    Cecile Rouleau
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Clin Cancer Res 14:7223-36. 2008
    ..Endosialin/CD248/tumor endothelial marker 1 is expressed in stromal cells, endothelial cells, and pericytes in various tumors; however, few studies have focused on expression in malignant cells...
  33. ncbi Murine endothelial cell lines as models of tumor endothelial cells
    Jennifer Walter-Yohrling
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Clin Cancer Res 10:2179-89. 2004
    ..These cells can be used in in vitro angiogenesis assays for evaluating the potential antiangiogenic properties and interspecies cross-reactivity of novel compounds...
  34. ncbi Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
    Beverly A Teicher
    Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701 9322, USA
    Biochem Pharmacol 75:1262-71. 2008
    ..A gene signature developed for topotecan sensitivity/resistance may have value in patient identification. Convergence of these efforts should result in clinically effective second generation TopoI inhibitors...
  35. ncbi TGF-beta in cancer and as a therapeutic target
    Jan Pinkas
    Genzyme Corporation, 1 Mountain Road, Framingham, MA 01721, United States
    Biochem Pharmacol 72:523-9. 2006
    ..Transforming growth factor-beta and its receptors are targets for antibody therapeutics and small molecule kinase inhibitors...
  36. ncbi Hypoxia, tumor endothelium, and targets for therapy
    Beverly A Teicher
    Adv Exp Med Biol 566:31-8. 2005
    ....
  37. ncbi Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta
    Victoria C Liu
    Department of Urology, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, IL 60611, USA
    J Immunol 178:2883-92. 2007
    ..In summary, we have demonstrated that tumor cells directly convert CD4+CD25- T cells to T(reg) cells through production of high levels of TGF-beta, suggesting a possible mechanism through which tumor cells evade the immune system...
  38. ncbi Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts
    Beverly A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Invest New Drugs 20:241-51. 2002
    ..8-fold increase in lifespan compared with carboplatin alone. 317615 x 2HCl is a promising new antiangiogenic agent that is in early phase clinical testing...
  39. ncbi Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology
    Kristan A Keyes
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Cancer Chemother Pharmacol 51:321-7. 2003
    ....
  40. ncbi LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice
    Kristan A Keyes
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Cancer Chemother Pharmacol 53:133-40. 2004
    ..Plasma VEGF was a weak marker of response to LY317615, and plasma bFGF and TGFbeta were not markers of LY317615 activity...
  41. ncbi Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption
    Enrique Alvarez
    Lilly Research Laboratories, Indianapolis, Indiana St Vincent s Institute of Medical Research, Melbourne, Fitzroy, Australia
    Clin Cancer Res 9:5705-13. 2003
    ..The results of this study demonstrate the ability of 13762 rat mammary carcinoma cells to elicit a measurable osteolysis and that bisphosphonates inhibit the tumor-induced bone resorption in this model...
  42. ncbi Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring
    Donald M McDonald
    University of California at San Francisco, San Francisco, CA, USA
    J Immunother 27:161-75. 2004
    ..The third addressed the translation to the clinic and monitoring of antiangiogenic activity of agents in patients and novel trial designs. What follows is a summary of the discussions and findings of each session...
  43. doi Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination
    Kent Perry
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Urology 72:225-9. 2008
    ..The present study was conducted to determine whether removal of TGF-beta from these tumor cells would inhibit tumor progression in vivo...
  44. ncbi Alterations in vascular gene expression in invasive breast carcinoma
    Belinda S Parker
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 64:7857-66. 2004
    ..Together, our results provide unique insights into vascular regulation in breast tumors and suggest specific roles for genes in driving tumor angiogenesis...
  45. ncbi Antiangiogenic effects of a protein kinase Cbeta-selective small molecule
    Beverly A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Cancer Chemother Pharmacol 49:69-77. 2002
    ..Protein kinase C frequently plays a central role in the intracellular signal transduction of growth factors and cytokines...
  46. ncbi Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003
    Paul Okunieff
    Department of Radiation Oncology, JP Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Am J Clin Oncol 26:522-9. 2003
    ..This hypothesis is ready for testing in cancers of the breast, prostate, colon, and in sarcomas. Enlarging the therapeutic window is a major goal that would allow for an increasingly favorable therapeutic gain...
  47. ncbi An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy
    Kristan Keyes
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Cancer Res 62:5597-602. 2002
    ..Although malignant cells alone secreted VEGF, stromal cells secreted TGF-beta and bFGF at levels comparable with or greater than malignant cells and thus may be important contributors to tumor growth and progression...
  48. ncbi Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions
    Giampietro Gasparini
    Division of Medical Oncology, S Filippo Neri Hospital, Rome, Italy
    J Clin Oncol 23:1295-311. 2005
    ....